Axial Spondyloarthritis and Cigarette Smoking

Kaut, Irène Kona; abourazzak, Fatima Ezzhara; Jamila, Essouri; Sènami, Florine Awassi; Diketa, Desiré; Harzy, Taoufik

doi:10.2174/1874312901711010053

Cited by 12 publications

(6 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, regarding the duration of symptoms, there was no significant difference between the smoker and nonsmoker AS patients. This was consistent with the results found by Kaut et al [52] and Gaber et al [53]. However, Sakellariou et al [35] found that smoking is positively associated with the duration of inflammatory backache.…”

Section: Discussionsupporting

confidence: 91%

Relationship between smoking, clinical, inflammatory, and radiographic parameters in patients with ankylosing spondylitis

Farouk

Abdel-Rahman

Hassan

2021

Egypt Rheumatol Rehabil

View full text Add to dashboard Cite

Background Ankylosing spondylitis (AS) is an autoimmune multisystemic disease that attacks the spine, sacroiliacs, and often causes asymmetrical peripheral oligoarthritis. It results from the interaction between the genetic factors mainly Human Leukocyte Antigen B27 (HLA B27) and environmental factors. Current smoking has been reported to be a major risk factor for the incidence and progression of ankylosing spondylitis. So, we aim to explore the relationship between smoking and each of the clinical, inflammatory markers, functional limitation, and radiographic progression in ankylosing spondylitis patients. Results Fifty ankylosing spondylitis patients were included in this study. Comparisons of clinical data, radiographic, and inflammatory markers among smokers and nonsmokers revealed that AS current smokers showed a statistically significant decrease in chest expansion, increase in the occiput to wall distance (p < 0.001**), higher inflammatory marker, higher disease activity indices (Ankylosing Spondylitis Disease Activity Score, Bath Ankylosing Spondylitis Disease Activity Index), higher Bath Ankylosing Spondylitis functional index, and modified Stoke Ankylosing Spondylitis Spine Score than nonsmokers (P < 0.001**). The smoking index was positively correlated with BASFI, ASDAS, (mSASSS) (r = 0.584, p = 0.005*) and negatively correlated with chest expansion. Conclusions Current smoking in ankylosing spondylitis patients is associated with higher disease activity, inflammatory markers, functional disability, and radiological progression. This may add to the disease burden and thus interferes with the personal daily activities, physical mobility, life quality, and the response to TNFi therapy. So, stopping smoking is a mandatory step in controlling the disease activity and having favorable outcome.

show abstract

Section: Discussionsupporting

confidence: 91%

Relationship between smoking, clinical, inflammatory, and radiographic parameters in patients with ankylosing spondylitis

Farouk

Abdel-Rahman

Hassan

2021

Egypt Rheumatol Rehabil

View full text Add to dashboard Cite

show abstract

“…36 Smoking is an important public health concern and increases the disease burden in SpA. 37 There is an association between smoking and radiographic progression, disease activity, inflammation and syndesmophyte formation. 38 – 40 Smoking is a modifiable lifestyle factor.…”

Section: Resultsmentioning

confidence: 99%

<p>Recommendation for the Management of Spondyloarthritis Patients in Kuwait</p>

Ali

Abutiban

Al-Awadhi

et al. 2020

OARRR

View full text Add to dashboard Cite

Objective: In 2016, ASAS and EULAR made joint recommendations for the management of patients with spondyloarthritis. Although Global and European perspectives are important, they cannot accurately reflect the situation for all patients in all countries and regions. As such, the group worked to tailor the existing international recommendations to suit the specific demographic needs of local populations in the Gulf region, with a specific focus on Kuwait. Methods: Recommendations drafted following a PubMed search for relevant literature were reviewed and then underwent Delphi vote to reach consensus on those to be included. Advice for newly approved agents, including targeted synthetic disease-modifying anti-rheumatic drugs, was included based on the group's clinical experience. Results: The resulting 41 recommendations are grouped into five categories covering key definitions and principles for the management and treatment of both axial and peripheral forms of spondyloarthritis. Conclusion: Through adaptation of existing guidelines and incorporating the current evidence and clinical experience of the members of the group, these recommendations have been developed to reflect the unique situation in Kuwait with regard to differing patient profiles, local culture and approved therapeutic approaches, and are designed to aid in clinical decision-making.

show abstract

“…Nearly half of the participants are smokers (46.8%). There is a strong relationship between smoking and the male gender and the severity of AS according to Kaut et al (26).…”

Section: Discussionmentioning

confidence: 98%

Comparison between Reference Infliximab (Remicade) and its Biosimilar (Remsima) in Patients with Ankylosing Spondylitis: A Field-based Pharmacoeconomic Study

Fadhil

Al‐Jumaili

Ani

2023

Al-Kindy Col. Med. J

View full text Add to dashboard Cite

Background: Ankylosing spondylitis is a chronic inflammatory disease that mostly involves the spine and sacroiliac joints. It is associated with a decreased quality of life. Biological medicines such as infliximab and its biosimilar are the mainstay treatments for active ankylosing spondylitis. Objective: The study objective was to conduct a pharmacoeconomic study comparing the cost-effectiveness of the reference infliximab with its biosimilar in ankylosing spondylitis patients visiting public hospitals. Subjects and Method: This is a two-center pharmacoeconomic study performed at two large teaching governmental hospitals in Baghdad, Iraq, which supplied infliximab to outpatients with ankylosing spondylitis. The outcome data were obtained from patient’s medical records and face-to-face interviews with the patients from December 2021 through April 2022. The Independent T-Test was used to measure the differences in areas of utility, and quality of life, between the two infliximab groups. Results: The study recruited 62 patients with ankylosing spondylitis who received infliximab (31 received Remicade, and 31 received Remsima) for at least 12 weeks at two public teaching hospitals. The mean age of the patients was 37.85 years and 83.9% were men. In general, both reference infliximab and its biosimilar were successful in increasing the quality of life. Their importation costs were different from 2019 to 2021. The incremental cost-effectiveness ratio of reference infliximab versus biosimilar was $ 40,909/quality-adjusted life year (QALY) according to 2019 pricing. In contrast, in 2021 reference infliximab (Remicade) was less expensive and yielded slightly better quality of life improvement than biosimilar (Remsima) making Remicade more cost-effective (dominant). Conclusion: Remicade was slightly superior to Remsima in quality of life improvement. However, it was difficult to determine whether the reference or its biosimilar was more cost-effective in 2019 because the health officials did not specify a willingness to pay per quality-adjusted life year. Compared to Remsima, Remicade was more cost-effective in 2021 because it was less expensive and more effective in terms of quality of life improvement.

show abstract

Axial Spondyloarthritis and Cigarette Smoking

Cited by 12 publications

References 31 publications

Relationship between smoking, clinical, inflammatory, and radiographic parameters in patients with ankylosing spondylitis

Relationship between smoking, clinical, inflammatory, and radiographic parameters in patients with ankylosing spondylitis

<p>Recommendation for the Management of Spondyloarthritis Patients in Kuwait</p>

Comparison between Reference Infliximab (Remicade) and its Biosimilar (Remsima) in Patients with Ankylosing Spondylitis: A Field-based Pharmacoeconomic Study

Contact Info

Product

Resources

About